OFFICE OF THE CLERK UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF NEW YORK

LAWRENCE K. BAERMAN CLERK JAMES T. FOLEY U.S. COURTHOUSE 445 BROADWAY, ROOM 509 ALBANY, NEW FORK 12207 (518) 257-1800

June 13. 2005

Clerk, US District Court 2300 United States Courthouse One Courthouse Way Boston, MA 02210-3002

> RE: Pharmaceutical Industry Average Wholesale Price Litigation MDL Docket # 1456 NDNY Case # 05-cv-397 GLS/GJD

Dear Clerk:

Enclosed herewith please find a certified copy of the Conditional Transfer Order and a certified copy of the docket sheet in the above-listed MDL case. As this case is completely electronic under ECF, you can view the original record by clicking on the "CM-ECF Quick Query" link on our intranet site at http://156.121.59.197/.

Please return the copy of this letter to my attention when you receive this. Thank you.

Sincerely, LAWRENCE K. BAERMAN, CLERK

By: Britney Norton Deputy Clerk

Enclosures	
ACKNOWLEDGMENT:	DATE:

CLOSED

U.S. District Court Northern District of New York [LIVE - Version 2.4] (Syracuse) CIVIL DOCKET FOR CASE #: 5:05-cv-00397-GLS-GJD

County of Tompkins v. Abbott Laboratories, Inc.

et al

Assigned to: Judge Gary L. Sharpe

Referred to: Magistrate Judge Gustave J. DiBianco Statutory Actions

Cause: 42:1396 - Tort Negligence

Date Filed: 03/31/2005 Jury Demand: Plaintiff Nature of Suit: 890 Other

Jurisdiction: Federal Question

Plaintiff

County of Tompkins

represented by Aaron D. Hovan

Kirby, McInerney Law Firm 830 Third Avenue New York, NY 10022 212-371-6600

Fax: 212-751-2540

Email: ahovan@kmslaw.com

LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Joanne M. Cicala

Kirby, McInerney Law Firm 830 Third Avenue New York, NY 10022 212-371-6600

Fax: 212-751-2540

Email: jcicala@kmslaw.com

LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Roger W. Kirby

Kirby, McInerney Law Firm 830 Third Avenue New York, NY 10022 212-371-6600

Fax: 212-751-2540

Filed 06/15/2005 Page 2 of 11

> Email: iramirez@kmslaw.com LEAD ATTORNEY ATTORNEY TO BE NOTICED

V.

Defendant

Abbott Laboratories, Inc.

Defendant

Agouron Pharmaceuticals, Inc.

Defendant

Alcon Laboratories, Inc.

Defendant

Allergan, Inc.

Defendant

Alpharma, Inc.

Defendant

Amgen, Inc.

Defendant

Andrx Corp.

Defendant

Astrazeneca Pharmaceuticals L.P.

Defendant

Aventis Pharmaceuticals, Inc.

Defendant

Barr Laboratories, Inc.

Defendant

Baxter International, Inc.

Defendant

Baxter Healthcare Corporation

Defendant

Bayer Corp.

Defendant

Ben Venue Laboratories, Inc.

Defendant

Berlex Laboratories, Inc.

Defendant

Biogen Idec, Inc.

Defendant

Biovail Pharmaceuticals, Inc.

Defendant

Boehringer Ingelheim Corp.

Defendant

Boehringer Ingelheim

Pharmaceuticals, Inc.

Defendant

Bristol-Meyers Squibb

Company

Defendant

Dermik Laboratories, Inc.

Defendant

Dey, Inc.

Defendant

Eisai, Inc.

Defendant

Eli Lilly and Company

Defendant

Endo Pharmaceuticals, Inc.

Defendant

Ethex Corp.

Defendant

Forest Laboratories, Inc.

Defendant

Forest Pharmaceuticals, Inc.

Defendant

Fujisawa Healthcare, Inc.

Defendant

Fujisawa USA, Inc.

Defendant

Genentech, Inc.

Defendant

Genzyme Corp.

Defendant

Gilead Sciences, Inc.

Defendant

Glaxosmithkline, P.L.C.

Defendant

Greenstone, Ltd.

Defendant

Hoffman-La Roche, Inc.

Defendant

Immunex Corp.

Defendant

Ivax Corp.

Defendant

Ivax Pharmaceuticals, Inc.

Defendant

Janssen Pharmaceutica

Products, LP

Defendant

Johnson & Johnson

Defendant

King Pharmaceuticals, Inc.

Defendant

McNeil-PPC, Inc.

Defendant

Medimmune, Inc.

Defendant

Merck & Co., Inc.

Defendant

Monarch Pharmaceuticals, Inc.

Defendant

Mylan Laboratories, Inc.

Defendant

Mylan Pharmaceuticals, Inc.

Defendant

Novartis Pharmaceuticals Corp.

Defendant

Novo Nordisk Pharmaceuticals, Inc.

Defendant

Oncology Therapeutics Network Corp.

Defendant

Organon Pharmaceuticals USA, Inc.

Defendant

Ortho Biotech Products LP

Defendant

Ortho-McNeil Pharmaceutical, Inc.

Defendant

Par Pharmaceutical, Inc.

Defendant

Pfizer, Inc.

Defendant

Pharmacia Corp.

Defendant

Purdue Pharma, L.P.

Defendant

Purepac Pharmaceutical Co.

Defendant

Reliant Pharmaceuticals

Defendant

Roche Laboratories, Inc.

Defendant

Roxane Laboratories, Inc.

Defendant

Sandoz, Inc.

Defendant

Sanofi-Synthelabo, Inc.

Defendant

Schering Corp.

Defendant

Schering-Plough Corp.

Defendant

Serono, Inc.

Defendant

Smithklinebeecham Corp.

doing business as Glaxosmithkline

Defendant

Takeda Pharmaceuticals North America, Inc.

Defendant

Tap Pharmaceutical Products, Inc.

Defendant

Teva Pharmaceutical USA, Inc.

Defendant

UCB Pharma, Inc.

Defendant

UDL Laboratories, Inc.

Defendant

Warrick Pharmaceuticals Corp.

Defendant

Watson Pharmaceuticals, Inc.

Defendant

Watson Pharma, Inc.

Defendant

Wyeth

Date Filed	#	Docket Text
03/31/2005	<u>1</u>	COMPLAINT against Alpharma, Inc., Amgen, Inc., Andrx Corp., Astrazeneca Pharmaceuticals L.P., Aventis Pharmaceuticals, Inc., Barr Laboratories, Inc., Baxter International, Inc., Baxter Healthcare Corporation, Bayer Corp., Ben Venue Laboratories, Inc., Berlex Laboratories, Inc., Biogen Idec, Inc., Biovail Pharmaceuticals, Inc., Boehringer Ingelheim Corp., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Meyers Squibb Company, Dermik Laboratories, Inc., Dey, Inc., Eisai, Inc., Eli Lilly and Company, Endo Pharmaceuticals, Inc., Ethex Corp., Forest Laboratories, Inc., Forest Pharmaceuticals, Inc., Fujisawa Healthcare, Inc., Fujisawa USA, Inc., Genentech, Inc., Genzyme Corp., Gilead Sciences, Inc., Glaxosmithkline, P.L.C., Greenstone, Ltd., Hoffman-La Roche, Inc., Immunex Corp., Ivax Corp., Ivax

	Pharmaceuticals, Inc., Janssen Pharmaceutica Products, LP, Johnson & Johnson, King Pharmaceuticals, Inc., McNeil-PPC, Inc., Medimmune, Inc., Merck & Co., Inc., Monarch Pharmaceuticals, Inc., Mylan Laboratories, Inc., Mylan Pharmaceuticals, Inc., Novartis Pharmaceuticals Corp., Novo Nordisk Pharmaceuticals, Inc., Oncology Therapeutics Network Corp., Organon Pharmaceuticals USA, Inc., Ortho Biotech Products LP, Ortho-McNeil Pharmaceutical, Inc., Par Pharmaceutical, Inc., Pfizer, Inc., Pharmacia Corp., Purdue Pharma, L.P., Purepac Pharmaceutical Co., Reliant Pharmaceuticals, Roche Laboratories, Inc., Roxane Laboratories, Inc., Sandoz, Inc., Sanofi-Synthelabo, Inc., Abbott Laboratories, Inc., Schering Corp., Schering-Plough Corp., Serono, Inc., Smithklinebeecham Corp., Takeda Pharmaceuticals North America, Inc., Tap Pharmaceutical Products, Inc., Teva Pharmaceutical USA, Inc., UCB Pharma, Inc., UDL Laboratories, Inc., Agouron Pharmaceuticals, Inc., Warrick Pharmaceuticals Corp., Watson Pharmaceuticals, Inc., Watson Pharma, Inc., Wyeth, Alcon Laboratories, Inc., Allergan, Inc. (Filing fee \$ 250 receipt number ALB000649) filed by County of Tompkins. (Attachments: # 1 Exhibit(s) Page 35-74# 2 Exhibit(s) Page 75-114# 3 Exhibit(s) Page 115-136# 4 Exhibit(s) A part 1# 5 Exhibit(s) A part 2# (6) Exhibit(s) A part 3# 7 Exhibit(s) A part 4# 8 Exhibit(s) A part 5# 9 Exhibit(s) B# (10) Exhibit(s) C# 11 Exhibit(s) D# 12 Exhibit(s) E)(ban) Additional attachment(s) added on 4/28/2005 (jel,). Additional attachment(s) added on 4/28/2005 (jel,). (Entered: 03/31/2005)
03/31/2005	Summons Issued as to Alpharma, Inc., Amgen, Inc., Andrx Corp., Astrazeneca Pharmaceuticals L.P., Aventis Pharmaceuticals, Inc., Barr Laboratories, Inc., Baxter International, Inc., Baxter Healthcare Corporation, Bayer Corp., Ben Venue Laboratories, Inc., Berlex Laboratories, Inc., Biogen Idec, Inc., Biovail Pharmaceuticals, Inc., Boehringer Ingelheim Corp., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Meyers Squibb Company, Dermik Laboratories, Inc., Dey, Inc., Eisai, Inc., Eli Lilly

		and Company, Endo Pharmaceuticals, Inc., Ethex Corp., Forest Laboratories, Inc., Forest Pharmaceuticals, Inc., Fujisawa Healthcare, Inc., Fujisawa USA, Inc., Genentech, Inc., Genzyme Corp., Gilead Sciences, Inc., Glaxosmithkline, P.L.C., Greenstone, Ltd., Hoffman-La Roche, Inc., Immunex Corp., Ivax Corp., Ivax Pharmaceuticals, Inc., Janssen Pharmaceutica Products, LP, Johnson & Johnson, King Pharmaceuticals, Inc., McNeil-PPC, Inc., Medimmune, Inc., Merck & Co., Inc., Monarch Pharmaceuticals, Inc., Mylan Laboratories, Inc., Mylan Pharmaceuticals, Inc., Novartis Pharmaceuticals Corp., Novo Nordisk Pharmaceuticals, Inc., Oncology Therapeutics Network Corp., Organon Pharmaceuticals USA, Inc., Ortho Biotech Products LP, Ortho-McNeil Pharmaceutical, Inc., Par Pharmaceutical, Inc., Pfizer, Inc., Pharmacia Corp., Purdue Pharma, L.P., Purepac Pharmaceutical Co., Reliant Pharmaceuticals, Roche Laboratories, Inc., Roxane Laboratories, Inc., Sandoz, Inc., Sanofi-Synthelabo, Inc., Abbott Laboratories, Inc., Schering Corp., Schering-Plough Corp., Serono, Inc., Smithklinebeecham Corp., Takeda Pharmaceuticals North America, Inc., Tap Pharmaceutical Products, Inc., Teva Pharmaceutical USA, Inc., UCB Pharma, Inc., UDL Laboratories, Inc., Agouron Pharmaceuticals, Inc., Warrick Pharmaceuticals Corp., Watson Pharmaceuticals, Inc., Watson Pharma, Inc., Wyeth, Alcon Laboratories, Inc., Allergan, Inc., (ban) (Entered: 04/01/2005)
03/31/2005	2	G.O. 25 FILING ORDER ISSUED Initial Conference set for 8/3/2005 02:30 PM in Syracuse before Magistrate Judge Gustave J. DiBianco. Civil Case Management Plan due by 7/25/2005. (ban) (Entered: 04/01/2005)
04/28/2005		CLERK'S CORRECTION OF DOCKET ENTRY - Exhibit A Part 3 and Exhibit C to the <u>1</u> complaint were corrupted. Exhibits have been rescanned and properly uploaded. (jel,) (Entered: 04/28/2005)
05/03/2005	3	Letter from Aaron Hovan, outside counsel for County of Tompkins requesting Adjournment of Deadlines. (Hovan, Aaron) (Entered: 05/03/2005)

05/04/2005	4	ORDER: granting the # 3 Letter Request filed by County of Tompkins. The Clerk terminated the Rule 16 conference and the civil case management plan deadlines. Status Report deadline set for 12/15/2005. Signed by Judge Gustave J. DiBianco on 5/4/05. (jmb) (Entered: 05/05/2005)
05/19/2005	<u>5</u>	NOTICE advising of Conditional Transfer. (alh) (Entered: 05/19/2005)
06/06/2005	<u>6</u>	TRANSFER ORDER. Case Transferred to District of Massachusetts for MDL (re Pharmaceutical industry average wholesale price litigation). Signed by Clerk of the Panel Michael J. Beck. (ban) (Entered: 06/13/2005)
06/13/2005		Case transferred to District of Massachusetts. Original file, certified copy of transfer order, and docket sheet sent. (ban) (Entered: 06/13/2005)

	PACE	ER Service (Center
	Tra	ansaction Rec	eipt
06/21/2005 15:24:15			
PACER Login:	us2510	Client Code:	
Description:	Docket Report	Search Criteria:	5:05-cv-00397-GLS-GJD
Billable Pages:	4	Cost:	0.32



Sarah Allison Thornton CLERK OF COURT UNITED STATES DISTRICT COURT

DISTRICT OF MASSACHUSETTS
OFFICE OF THE CLERK
1 COURTHOUSE WAY
BOSTON, MASSACHUSETTS 02210

S. DISTRICT COURT

LAWRENCE K. DAERMAN, CLERK

ALBANY

1.2005 JUN

June 8, 2005

Mr. Larry Baerman, Clerk 345 James T. Foley U.S. Courthouse 445 Broadway Albany, NY 12207

IN RE: MDL DOCKET No. 1456 In Re: Pharmaceutical Industry Average
Wholesale Price Litigation

USDC - Massachusetts Lead Case No. 1:01CV12257-PBS

Your Case: Civil Action Nos:

1:05-408 County of Washington v. Abbott Labs, Inc. et al 1:05-422 County of Rensselaer v. Abbott Labs, Inc. et al 1:05-425 County of Albany v. Abbott Labs, Inc. et al 1:05-468 County of Warren v. Abbott Labs, Inc. et al 1:05-474 County of Greene v. Abbott Labs, Inc. et al 1:05-478 County of Saratoga v. Abbott Labs, Inc. et al

District of MA No: 1:05-11180 District of MA No: 1:05-11181

District of MA No: 1:05-11182 District of MA No: 1:05-11183

District of MA No: 1:05-11184 District of MA No: 1:05-11185

Dear Mr. Baerman:

Enclosed is a certified copy of the Order of the Judicial Panel on Multi-District Litigation, transferring the cases on the attached listing to the U.S. District Court for the District of Massachusetts for coordinated or consolidated pretrial proceedings pursuant to Title 28 United States Code Section 1407. These cases have been assigned to the Honorable Patti B. Saris.

In accordance with the Rules concerning Multi-District Litigation, please forward the original case file, along with a certified copy of the docket entries and a copy of the transfer order for the case now pending in your district as indicated above. Also include a copy of this letter when transmitting your records to the above address.

Your prompt attention to this matter is greatly appreciated. If you should have any questions, please do not hesitate to contact the undersigned at 617-748-9113, Robert Alba, Courtroom Clerk for Judge Saris at 617-748-9175 or Christine Patch, Docket Clerk for Judge Saris, at 617-748-9178.

Sincerely,


Kimberly M. Abaid Deputy Clerk

berly M. abaic

Information Copy to:

Michael Beck, Clerk of the Panel

Counsel of Record Robert Alba Christine Patch



IN RE PHARMACEUTICAL INDUSTRY AVERAGE WHOLESALE PRICE LITIGATION

(SEE ATTACHED SCHEDULE)

CONDITIONAL TRANSFER ORDER (CTO-21)

On April 30, 2002, the Panel transferred 16 civil actions to the United States District Court for the District of Massachusetts for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. Since that time, 35 additional actions have been transferred to the District of Massachusetts. With the consent of that court, all such actions have been assigned to the Honorable Patti B. Saris.

It appears that the actions on this conditional transfer order involve questions of fact which are common to the actions previously transferred to the District of Massachusetts and assigned to Judge Saris.

Pursuant to Rule 7.4 of the Rules of Procedure of the Judicial Panel on Multidistrict Litigation, 199 F.R.D. 425, 435-36 (2001), these actions are transferred under 28 U.S.C. § 1407 to the District of Massachusetts for the reasons stated in the order of April 30, 2002, 201 F.Supp.2d 1378 (J.P.M.L. 2002), and, with the consent of that court, assigned to the Honorable Patti B. Saris.

This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the District of Massachusetts. The transmittal of this order to said Clerk shall be stayed fifteen (15) days from the entry thereof and if any party files a notice of opposition with the Clerk of the Panel within this fifteen (15) day period, the stay will be continued until further order of the Panel.

Inasmuch as no objection is pending at this time, the stay is lifted.

MAY 3 1 2005

CLERK'S OFFICE
JUDICIAL PANEL ON
MULTIDISTRICT LITIGATION

FOR THE PANEL:

Michael J. Beck Clerk of the Panel

SCHEDULE CTO-21 - TAG-ALONG ACTIONS DOCKET NO. 1456 IN RE PHARMACEUTICAL INDUSTRY AVERAGE WHOLESALE PRICE LITIGATION

DIST. DIV. C.A. #	CASE CAPTION
NEW YORK NORTHERN	,
NYN I 05-408	The County of Washington v. Abbott Laboratories, Inc., et al.
NYN 1 05-422	County of Rensselaer v. Abbott Laboratories, Inc., et al.
NYN 1 05-425	County of Albany v. Abbott Laboratories, Inc., et al.
NYN 1 05-468	County of Warren v. Abbott Laboratories, Inc., et al.
NYN 1 05-474	County of Greene v. Abbott Laboratories, Inc., et al.
NYN 1 05-478	County of Saratoga v. Abbott Laboratories, Inc., et al.
NYN 3 05-354	County of Chenango v. Abbott Laboratories, Inc., et al.
NYN 3 05-456	The County of Broome v. Abbott Laboratories, Inc., et al.
NYN 5 05-397	County of Tompkins v. Abbott Laboratories, Inc., et al.
NYN 5 05-423	County of Cayuga v. Abbott Laboratories, Inc., et al.
NYN 6 05-415	County of Herkimer, New York v. Abbott Laboratories, Inc., et al.
NYN 6 05-489	County of Oneida v. Abbott Laboratories, Inc., et al.
NYN 7 05-479	County of Saint Lawrence v. Abbott Laboratories, Inc., et al.
NEW YORK WESTERN	
NYW I 05-214	County of Chautauqua v. Abbott of Laboratories, Inc., et al.
NYW 1 05-236	County of Allegany v. Abbott Laboratories, Inc., et al.
NYW 1 05-256	County of Cattaraugus v. Abbott Laboratories, Inc., et al.
NYW-1 05-259	County of Eric v. Abbott Laboratories, Inc., et al. Opposed 5/24/05
NYW 6 05-6138	County of Wayne v. Abbott Laboratories, et al.
NYW 6 05-6148	County of Monroe v. Abbott Laboratories, Inc., et al.
NYW 6 05-6172	County of Yates v. Abbott Laboratories, Inc., et al.